Enoxolone in Major Depression - Biomarker-outcome Relationship
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
Many different forms of depression exist. It is difficult to predict to what treatment a
given patient with depression responds. Studies demonstrate that biomarkers can help to
distinguish different forms of depression. Simple markers, like aldosterone from the saliva,
blood pressure and inflammation markers from the blood, have been identified as predictors of
a more difficult to treat depression. Enoxolone is a molecule derived from the licorice plant
and has demonstrated an effect on these biomarkers, which may indicate a better response. In
a randomized placebo controlled trial this study is assessing whether the administration of
enoxolone vs. placebo can change these markers and if patients benefit from these biomarker
changes clinically. In addition, this study records the volume and structure of certain brain
areas, which could be involved in this action.